Cyclopharm (ASX:CYC) LT-Debt-to-Total-Asset: 0.16 (As of Dec. 2025)

What is Cyclopharm LT-Debt-to-Total-Asset?

Cyclopharm ASX:CYC -4.08% 46 LT-Debt-to-Total-Asset is 0.16 as of Dec. 2025. GuruFocus rates ASX:CYC with a GF Score™ of 46/100 and a GF Value™ of A$0.84 (Possible Value Trap). The stock has 7 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cyclopharm's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.16.

Cyclopharm's long-term debt to total assets ratio increased from Dec. 2024 (0.12) to Dec. 2025 (0.16). It may suggest that Cyclopharm is progressively becoming more dependent on debt to grow their business.

Cyclopharm (ASX:CYC) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Cyclopharm LT-Debt-to-Total-Asset Related Terms

Cyclopharm LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Cyclopharm's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyclopharm LT-Debt-to-Total-Asset Chart

Cyclopharm Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.08

0.09

0.12

0.16

Cyclopharm Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.09	0.07	0.12	0.13	0.16

46GF Score

Cyclopharm Ltd ASX:CYC

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cyclopharm LT-Debt-to-Total-Asset Calculation

Cyclopharm's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	7.18	/	46.101
	=	0.16

Cyclopharm's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	7.18	/	46.101
	=	0.16

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.16 mean?

Cyclopharm (ASX:CYC) has a LT-Debt-to-Total-Asset of 0.16 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cyclopharm and its competitors.

Is Cyclopharm's LT-Debt-to-Total-Asset too high?

Cyclopharm's current LT-Debt-to-Total-Asset is 0.16. Overall, Cyclopharm has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Cyclopharm's LT-Debt-to-Total-Asset compare to MCK and CAH?

Cyclopharm's LT-Debt-to-Total-Asset of 0.16 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Distribution company?

A good LT-Debt-to-Total-Asset depends on the Medical Distribution industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cyclopharm and its competitors. Cyclopharm's current LT-Debt-to-Total-Asset is 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cyclopharm stock overvalued right now?

Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.84, compared to a current price of A$0.47 — trading 44% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.16. Cyclopharm's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current LT-Debt-to-Total-Asset is 0.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyclopharm (ASX:CYC) Overvalued in 2026?

Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued. The current stock price of A$0.47 is trading 44% below its estimated GF Value™ of A$0.84. GuruFocus considers Cyclopharm to be Possible Value Trap.

Key valuation signals for ASX:CYC:

LT-Debt-to-Total-Asset: 0.16
GF Value™: A$0.84 vs. price of A$0.47 (44% below fair value)
GF Score™: 46/100 with 7 warning signs

No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cyclopharm Business Description

Industry Healthcare Medical Distribution

Comparable Companies ASX:MYX ASX:PGC MCK CAH COR ASX:SIG HSIC SHSE:601607 HKSE:01099 XSWX:GALE SHSE:600332 SHSE:600998 TSE:7459 OSTO:ASKER MIL:AMP SHSE:600511 IST:SELEC NZSE:EBO TSE:2784 SHSE:600739

Address 1 The Crescent, Unit 4, Kingsgrove, Sydney, NSW, AUS, 2208

Website https://cyclopharm.com.au

Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.

46GF Score

Get the complete analysis for ASX:CYC

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.47

Price

A$0.84

GF Value

View ASX:CYC Analysis

See LT-Debt-to-Total-Asset data for all stocks →